Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) with a maintained price target of $25.
April 16, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on SAB Biotherapeutics with a price target of $25, as per analyst Keay Nakae.
The reaffirmation of a Buy rating and a significant price target of $25 by Chardan Capital, as analyzed by Keay Nakae, suggests a strong bullish outlook for SAB Biotherapeutics. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term, given the analyst's confidence in the company's prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100